BioInvent International AB Year-end Report January 1 - December 31, 2023

LUND, SWEDEN / ACCESSWIRE / February 22, 2024 / BioInvent International (STO:BINV) "2023 was a landmark year for BioInvent with positive clinical readouts from three Phase 1/2 programs. These data, supported by validating partnerships, a strong cash position and solid investor base, set BioInvent up to have a breakout year in 2024, fueled by expectations for substantial clinical progress across our pipeline." - Martin Welschof, CEO of BioInvent.

Events in the fourth quarter

• Positive data from clinical Phase 1/2a trial of BI-1808 as single agent were presented at SITC
• Preclinical data providing clear evidence of the potential of anti-TNFR2 antibody BI-1910 were presented at SITC
• Positive first clinical data on anti-FcyRIIB antibody BI-1607 presented at the San Antonio Breast Cancer Symposium
• First patient enrolled in Phase 1/2a clinical trial with TNFR2 antibody BI-1910
• BioInvent and Transgene announced that the first patient had been treated in Part B of Phase 1 trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA (pembrolizumab)

Events after the end of the period

• Supply agreement signed with AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence
• BioInvent regained the rights to immuno-oncology targets from Exelixis

Earlier during 2023, in brief

• (R) BioInvent selected to The Leukemia & Lymphoma Society's Therapy Acceleration Program and received USD 3 million strategic equity investment
• (R) A fourth complete response announced in Phase 1/2 trial with BI-1206 in non-Hodgkin's lymphoma
• Management strengthened with the appointment of Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs
• (R) BioInvent and Transgene reported positive Phase 1a data on oncolytic virus BT-001 in solid tumors
• (R) Additional efficacy data announced from intravenous part of Phase 1/2 trial with BI-1206 in solid tumors
• (R) Strong interim safety data and early signs of efficacy reported in Phase 1/2a trial with anti-TNFR2 antibody BI-1808 in advanced malignancies
• Research milestone event achieved in the collaboration with Exelixis, triggering a USD 1 million milestone payment

(R)= Regulatory event